MARKET

LIMN

LIMN

Liminatus Pharma
NASDAQ
0.6100
-0.0340
-5.28%
After Hours: 0.6200 +0.01 +1.64% 16:54 12/31 EST
OPEN
0.6225
PREV CLOSE
0.6440
HIGH
0.6456
LOW
0.6100
VOLUME
83.95K
TURNOVER
--
52 WEEK HIGH
33.66
52 WEEK LOW
0.6100
MARKET CAP
16.51M
P/E (TTM)
-7.0034
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LIMN last week (1222-1226)?
Weekly Report · 12/29/2025 10:24
Weekly Report: what happened at LIMN last week (1215-1219)?
Weekly Report · 12/22/2025 10:24
Weekly Report: what happened at LIMN last week (1208-1212)?
Weekly Report · 12/15/2025 10:32
Weekly Report: what happened at LIMN last week (1201-1205)?
Weekly Report · 12/08/2025 10:31
Weekly Report: what happened at LIMN last week (1124-1128)?
Weekly Report · 12/01/2025 10:26
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 11/26/2025 21:07
Liminatus Pharma Faces Nasdaq Non-Compliance Notice
TipRanks · 11/25/2025 22:49
Liminatus Pharma Faces Nasdaq Delisting Over Market Value Rule Breach
Reuters · 11/25/2025 22:27
More
About LIMN
Liminatus Pharma, Inc. is a pre-clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies. The Company is engaged in the development of a second generation CD47 blockade antibody designed to prevent the induction of severe anemia and thrombocytopenia observed with first generation CD47 blockades. The Company’s candidate, IBA101, is a humanized anti-CD47 monoclonal antibody. The CD47 checkpoint inhibitor’s initial indication is expected to be patients with advanced solid cancers, including non-small cell lung cancer. IBA101 is a humanized anti-human CD47 monoclonal antibody with a human IgG4 Fc, designed to preferentially bind nucleated cells, such as immune and tumor cells, while sparing anucleate cells like red blood cells and platelets. IBA101 promotes macrophage-mediated phagocytosis of tumor cells.

Webull offers Liminatus Pharma Inc stock information, including NASDAQ: LIMN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LIMN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LIMN stock methods without spending real money on the virtual paper trading platform.